The socioeconomic impact of narcolepsy.

作者: Richard Dodel , Helga Peter , Tobias Walbert , Annika Spottke , Carmen Noelker

DOI: 10.1093/SLEEP/27.6.1123

关键词:

摘要: STUDY OBJECTIVE To evaluate the economic burden of patients suffering from narcolepsy. DESIGN Cross-sectional study. PARTICIPANTS 75 narcoleptic diagnosed at Hephata Klinik, Germany, who met International Classification Sleep Disorders criteria for MEASUREMENTS A standardized telephone interview was used to inquire about disease and its burden. In addition, health-related quality life scales (SF-36 EQ-5D) were mailed patients. Complete data available Direct indirect costs calculated societal perspective. All (mean +/- SD) in 2002 Euros (Euros). RESULTS Total annual 14,790 16,180 (US-dollars 15,410) per patient. 3,180 3,540 3,310), which consisted hospital (Euros 1,210 2,210; US-dollars 1,260), drug (narcolepsy medication: 1,020 1,420; 1,060), ambulatory care 90 90; 40), diagnostics 20 30; 20). More than 50% due newer wake-promoting drugs. amounted 11,390 15,740 11,860) patient mainly attributable early retirement disease. Narcolepsy listed as being cause unemployment by 32 with sleep attacks, there a significant correlation between higher compared without these attacks. CONCLUSIONS causes high socioeconomic burden, is comparable other chronic neurologic diseases, Indirect are considerably direct costs. Measures should be taken increase public awareness this Appropriate treatment must provided order assist continuing working life.

参考文章(26)
Roger Broughton, Quais Ghanem, Yasuo Hishikawa, Yoshiro Sugita, Sonia Nevsimalova, Bedrich Roth, Life Effects of Narcolepsy in 180 Patients from North America, Asia and Europe Compared to Matched Controls Canadian Journal of Neurological Sciences. ,vol. 8, pp. 299- 304 ,(1981) , 10.1017/S0317167100043419
Ritanserin improves sleep quality in narcolepsy. Pharmacopsychiatry. ,vol. 36, pp. 150- 155 ,(2003) , 10.1055/S-2003-41200
William A. Broughton, Roger J. Broughton, Psychosocial Impact of Narcolepsy Sleep. ,vol. 17, pp. S45- S49 ,(1994) , 10.1093/SLEEP/17.SUPPL_8.S45
C Hublin, M Partinen, J Kaprio, M Koskenvuo, C Guilleminault, Epidemiology of Narcolepsy Sleep. ,vol. 17, pp. S7- S12 ,(1994) , 10.1093/SLEEP/17.SUPPL_8.S7
C. Hoffmann, O. Schöffski, J.-M. Graf v. d. Schulenburg, Die Standardisierung der Methodik im In- und Ausland Gesundheitsökonomische Evaluationen. pp. 421- 470 ,(2000) , 10.1007/978-3-662-11871-9_15
Michael J. Thorpy, Jonathan R. L. Schwartz, Ruzica Kovacevic-Ristanovic, Roza Hayduk, Initiating treatment with modafinil for control of excessive daytime sleepiness in patients switching from methylphenidate: an open-label safety study assessing three strategies Psychopharmacology. ,vol. 167, pp. 380- 385 ,(2003) , 10.1007/S00213-002-1343-4
Emmanuel Mignot, Gert Jan Lammers, Beth Ripley, Michele Okun, Sonia Nevsimalova, Sebastiaan Overeem, Jitka Vankova, Jed Black, John Harsh, Claudio Bassetti, Harald Schrader, Seiji Nishino, The Role of Cerebrospinal Fluid Hypocretin Measurement in the Diagnosis of Narcolepsy and Other Hypersomnias Archives of Neurology. ,vol. 59, pp. 1553- 1562 ,(2002) , 10.1001/ARCHNEUR.59.10.1553
Colin M. Shapiro, Jamil L. Hossain, The prevalence, cost implications, and management of sleep disorders: an overview. Sleep and Breathing. ,vol. 6, pp. 85- 102 ,(2002) , 10.1007/S11325-002-0085-1